Dicerna Pharmaceuticals
Biopharmaceutical company that developed RNA interference (RNAi) therapeutics using its proprietary GalXC platform. Acquired by Novo Nordisk in 2021.
Notes
Dicerna Pharmaceuticals was a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics using its proprietary GalXC (GalNAc-siRNA conjugate) platform. The company developed treatments targeting liver-expressed genes for rare diseases, viral infections, and cardiometabolic conditions.
Dicerna was acquired by Novo Nordisk in December 2021 for approximately $3.3 billion. The acquisition provided Novo Nordisk with RNAi capabilities and Dicerna's GalXC technology platform, which enables targeted delivery of RNAi therapeutics to the liver.
Prior to the acquisition, Dicerna was publicly traded on NASDAQ (DRNA) and had multiple clinical programs in development, including partnerships with major pharmaceutical companies.
Team (Pre-Acquisition)
- Douglas M. Fambrough, Ph.D. - Former President & CEO
- Robert D. Brown, M.D. - Former Chief Medical Officer
Additional Research Findings
- Founded in 2006
- Headquartered in Lexington, Massachusetts
- Acquired by Novo Nordisk in December 2021 for ~$3.3 billion
- Proprietary GalXC platform for liver-targeted RNAi delivery
- Former NASDAQ listing: DRNA
- Multiple pharma partnerships including Roche, Eli Lilly, Alexion
- Key programs included treatments for chronic hepatitis B, NASH, and rare diseases
- Now operates as part of Novo Nordisk